Chen Geng, Bláhová Jana, Staffen Nico, Hübner Harald, Nunhöfer Nadja, Qiu Chen, Gmeiner Peter, Weikert Dorothee, Du Yang, Xu Jun
School of Medicine, Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, China.
Kobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, China.
Nat Commun. 2025 Aug 27;16(1):7988. doi: 10.1038/s41467-025-63422-1.
Allosteric modulators have gained substantial interest in current GPCR drug discovery. Here, we present a mechanism of allosteric modulation involving the dimerization of GPR3, a promising drug target for metabolic diseases and central nervous system disorders. We show that GPR3 forms constitutive homodimers in live cells and reveal that the inhibitor AF64394 functions as a negative allosteric modulator (NAM) specifically targeting dimeric GPR3. Using cryogenic electron microscopy (cryo-EM), we determine the structures of the AF64394-bound GPR3 dimer and its dimer-Gs signaling complex. These high-resolution structures reveal that AF64394 binds to the transmembrane dimer interface. AF64394 binding prevents the dissociation of the GPR3 dimer upon engagement with Gs and restrains transmembrane helix 5 in an inactive-like intermediate conformation, leading to reduced coupling with Gs. Our studies unveil a mechanism of dimer-specific inhibition of signaling with significant implications for the discovery of drugs targeting GPCRs capable of dimerization.
变构调节剂在当前G蛋白偶联受体(GPCR)药物研发中备受关注。在此,我们提出一种变构调节机制,该机制涉及GPR3的二聚化,GPR3是代谢疾病和中枢神经系统疾病的一个有前景的药物靶点。我们发现GPR3在活细胞中形成组成型同源二聚体,并揭示抑制剂AF64394作为一种负性变构调节剂(NAM),特异性靶向二聚体GPR3。利用低温电子显微镜(cryo-EM),我们确定了结合AF64394的GPR3二聚体及其二聚体-Gs信号复合物的结构。这些高分辨率结构显示AF64394结合到跨膜二聚体界面。AF64394的结合可防止GPR3二聚体在与Gs结合时解离,并将跨膜螺旋5限制在类似无活性的中间构象,导致与Gs的偶联减少。我们的研究揭示了一种二聚体特异性信号抑制机制,这对发现靶向能够二聚化的GPCR的药物具有重要意义。